I'm LongbridgeAI, I can summarize articles.WIT DYNE released its 2024 annual report, with operating revenue of 2.134 billion yuan, a year-on-year decrease of 14.08%; net profit attributable to shareholders of 516 million yuan, a year-on-year decrease of 11.9%; net profit excluding non-recurring gains and losses of 491 million yuan, a year-on-year decrease of 13.97%; basic earnings per share of 2.20 yuan/share. The company plans to distribute a cash dividend of 20 yuan (including tax) for every 10 shares to all shareholders. Revenue from the pharmaceutical business was 2.1 billion yuan, accounting for 98.23% of the main business revenue
According to the Zhitong Finance APP, WIT DYNE (000915.SZ) released its annual report for 2024, reporting an operating income of 2.134 billion yuan, a year-on-year decrease of 14.08%; net profit attributable to shareholders of the listed company was 516 million yuan, a year-on-year decrease of 11.90%; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 491 million yuan, a year-on-year decrease of 13.97%; basic earnings per share were 2.20 yuan/share. The company plans to distribute a cash dividend of 20 yuan (including tax) for every 10 shares to all shareholders.
The company primarily engages in the pharmaceutical business, and during the reporting period, revenue from the pharmaceutical industry was 2.1 billion yuan, accounting for 98.23% of the company's main business income